Patent classifications
A61K36/484
FRUCTUS FORSYTHIAE AND RADIX ASTRAGALI COMPOUND PREPARATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.
FRUCTUS FORSYTHIAE AND RADIX ASTRAGALI COMPOUND PREPARATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.
Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof
Provided are a pharmaceutical composition, a quasi-drug composition, a feed additive, a drinking water additive, a feed, and a drinking water for preventing, ameliorating, or treating porcine epidemic diarrhea (PED) virus infection, each including, as an active ingredient, a complex including a curcuminoid-based compound and a licorice extract or a fraction thereof.
Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof
Provided are a pharmaceutical composition, a quasi-drug composition, a feed additive, a drinking water additive, a feed, and a drinking water for preventing, ameliorating, or treating porcine epidemic diarrhea (PED) virus infection, each including, as an active ingredient, a complex including a curcuminoid-based compound and a licorice extract or a fraction thereof.
Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof
Provided are a pharmaceutical composition, a quasi-drug composition, a feed additive, a drinking water additive, a feed, and a drinking water for preventing, ameliorating, or treating porcine epidemic diarrhea (PED) virus infection, each including, as an active ingredient, a complex including a curcuminoid-based compound and a licorice extract or a fraction thereof.
ORAL GEL COMPOSITIONS
Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of herbal oils and extracts comprising (a) clove oil and/or eugenol (e.g., clove leaf oil and/or clove bud oil), (b) a cooling agent (e.g., menthol), (c) camphor, (d) an antimicrobial agent, e.g., turmeric and/or curcumin extract (e.g., turmeric, white turmeric (e.g., white curcumin) and (e) licorice; in an orally acceptable gel base, the gel base comprising one or more nonionic surfactants, the formulation providing a sustained release of the mixture of herbal oils and extracts following application to a tooth or gums; together with methods of making and using the same.
ORAL GEL COMPOSITIONS
Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of herbal oils and extracts comprising (a) clove oil and/or eugenol (e.g., clove leaf oil and/or clove bud oil), (b) a cooling agent (e.g., menthol), (c) camphor, (d) an antimicrobial agent, e.g., turmeric and/or curcumin extract (e.g., turmeric, white turmeric (e.g., white curcumin) and (e) licorice; in an orally acceptable gel base, the gel base comprising one or more nonionic surfactants, the formulation providing a sustained release of the mixture of herbal oils and extracts following application to a tooth or gums; together with methods of making and using the same.
FORMULATIONS AND USES THEREOF
Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.
FORMULATIONS AND USES THEREOF
Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.
Method for separating eight components in Chinese traditional medicine composition
The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-β-D-glucopyranoside, quercitrin, matairesinol-4′-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.